Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.

Gilead Sciences Inc. closed $3.98 short of its 52-week high ($87.87), which the company achieved on January 19th.

Shares of Gilead Sciences Inc. GILD dropped 0.13% to $83.05 Tuesday, on what proved to be an all-around mixed trading session ...

IBBQ is a relatively new US biotech ETF that competes with established peers like IBB and XBI. Read why I don't recommend ...

Today, Benzinga's options scanner spotted 9 options trades for Gilead Sciences. This is not a typical pattern. The sentiment ...

Gilead Sciences (GILD) stock price has staged a strong comeback this year, helped by strong earnings and a recent $40 million ...

In the latest supply deal on the active pharmaceutical ingredients (API) front, Gilead Sciences has tapped South Korea’s ...

AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival ...

Gilead Sciences’ Kite Pharma will sell its stake in China’s Fosun Kite Biotechnology nearly eight years after forming the ...

The latest trading day saw Gilead Sciences (GILD) settling at $83.08, representing a -0.1% change from its previous close.

AstraZeneca stock slumped Monday after its Daiichi Sankyo-partnered drug missed its mark in a study of patients with breast ...

NORTHAMPTON, MA / ACCESSWIRE / September 18, 2024 / Gilead SciencesJackson Egen learned the value of basic lab research as a graduate student at UC Berkeley in the 90s while working under the directio ...